Merck & Co. (MRK)'s Patrick Magri Elected National Pharmaceutical Council's Chairman Of The Board

WASHINGTON, Nov. 6, 2015 /PRNewswire-USNewswire/ -- The National Pharmaceutical Council (NPC) today announced that Patrick Magri, senior vice president, managed markets and policy, Merck, has been elected chairman of its Board of Directors for 2015-2016. Mr. Magri has served on NPC's Board of Directors since 2013.

Patrick Magri, senior vice president, managed markets and policy, Merck, has been elected chairman of the National Pharmaceutical Council's Board of Directors.
"Patrick's considerable expertise has been invaluable in our efforts to expand NPC's research and communications while he has served on the Board," said NPC President Dan Leonard. "As we address the changing health care environment, I know his guidance will help us to constructively address ongoing and emerging health policy challenges."

Mr. Magri has had a long, distinguished career at Merck. He joined Merck in 1990, working in a number of positions of increasing responsibility across the company, and has extensive experience with health care stakeholders and in a range of therapeutic areas. Since 2012, he has served as the senior vice president overseeing managed markets and policy in the United States.

"I am honored to have the opportunity to serve as the chairman of NPC's Board of Directors," Mr. Magri said. "NPC is leading the way on conducting research and communicating about critical health policy issues, including the value of medicines in achieving better patient health. I look forward to working with my fellow Board members to further NPC's mission to foster a supportive environment for medical innovation."

As the health policy debate has focused more on evidence and quality as drivers for change in the health care system, NPC has filled an important role in the discussion by supporting and conducting peer-reviewed research focused on evidence, the value of medicines for patients, and innovation. For more than 60 years, the organization has focused on advancing research, information dissemination, and education.

The NPC Board also elected Joshua J. Ofman, MD, MSHS, senior vice president, global value access & policy, Amgen, Inc., as vice chair; Jeffrey R. Stewart, vice president, U.S. commercial operations, AbbVie, as treasurer; and Richard H. Bagger, senior vice president, corporate affairs and market access, Celgene Corporation, to serve on the Executive Committee.

About the National Pharmaceutical Council
The National Pharmaceutical Council is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation. Founded in 1953 and supported by the nation's major research-based pharmaceutical companies, NPC focuses on research development, information dissemination, and education on the critical issues of evidence, innovation and the value of medicines for patients. For more information, visit www.npcnow.org and follow NPC on Twitter @npcnow.

Photo - http://photos.prnewswire.com/prnh/20151106/284639

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mercks-patrick-magri-elected-national-pharmaceutical-councils-chairman-of-the-board-300174083.html

SOURCE National Pharmaceutical Council

Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i